Literature DB >> 22223452

Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.

Prabhakar Deonikar1, Mahendra Kavdia.   

Abstract

In sickle cell disease, the changes in RBC morphology destabilize the red blood cell (RBC) membrane and lead to hemolysis. Several experimental and clinical studies have associated intravascular hemolysis with pulmonary hypertension in sickle cell disease. Cell-free hemoglobin (Hb) from intravascular hemolysis has high affinity for nitrixc oxide (NO) and can affect the NO bioavailability in the sickle cell disease, which may eventually lead to pulmonary hypertension. To study the effects of intravascular hemolysis related cell-free Hb concentrations on NO bioavailability, we developed a two-dimensional mathematical model of NO biotransport in 50-μm arteriole under steady-state sickle cell disease conditions. We analyzed the effects of flow-dependent NO production and axial and radial transport of NO, a recently reported much lower NO-RBC reaction rate constant, and cell-free layer thickness on NO biotransport. Our results show that the presence of cell-free Hb concentrations as low as 0.5 μM results in an approximately three- to sevenfold reduction in the predicted smooth muscle cell NO concentrations compared with those under physiological conditions. In addition, increasing the diffusional resistance for NO in vascular lumen from cell-free layer or reducing NO-RBC reaction rate did not improve the NO bioavailability at the smooth muscle cell layer significantly for cell-free Hb concentrations ≥1 μM. These results suggest that lower NO bioavailability due to low micromolar cell-free Hb can disturb NO homeostasis and cause insufficient bioavailability at the smooth muscle cell layer. Our results supports the hypothesis that hemolysis-associated reduction in NO bioavailability may play a role in the development of pathophysiological complications like pulmonary hypertension in sickle cell disease that are observed in several clinical and experimental studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223452      PMCID: PMC3331583          DOI: 10.1152/japplphysiol.01173.2011

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  76 in total

Review 1.  Management of sickle cell disease.

Authors:  M H Steinberg
Journal:  N Engl J Med       Date:  1999-04-01       Impact factor: 91.245

2.  Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease.

Authors:  J B Schnog; T Teerlink; F P L van der Dijs; A J Duits; F A J Muskiet
Journal:  Ann Hematol       Date:  2004-12-14       Impact factor: 3.673

Review 3.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Authors:  Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

4.  In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse.

Authors:  S H Embury; N Mohandas; C Paszty; P Cooper; A T Cheung
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  Intravascular flow decreases erythrocyte consumption of nitric oxide.

Authors:  J C Liao; T W Hein; M W Vaughn; K T Huang; L Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  Estimation of nitric oxide production and reaction rates in tissue by use of a mathematical model.

Authors:  M W Vaughn; L Kuo; J C Liao
Journal:  Am J Physiol       Date:  1998-06

7.  Diffusion of nitric oxide and scavenging by blood in the vasculature.

Authors:  A R Butler; I L Megson; P G Wright
Journal:  Biochim Biophys Acta       Date:  1998-09-16

8.  Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin.

Authors:  D H Doherty; M P Doyle; S R Curry; R J Vali; T J Fattor; J S Olson; D D Lemon
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

9.  Diffusion-limited reaction of free nitric oxide with erythrocytes.

Authors:  X Liu; M J Miller; M S Joshi; H Sadowska-Krowicka; D A Clark; J R Lancaster
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

10.  The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes.

Authors:  E CARLSEN; J H COMROE
Journal:  J Gen Physiol       Date:  1958-09-20       Impact factor: 4.086

View more
  5 in total

Review 1.  Updated role of nitric oxide in disorders of erythrocyte function.

Authors:  Marc J Kahn; Jason H Maley; George F Lasker; Philip J Kadowitz
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2013-03-01

Review 2.  Hemoglobin-mediated nitric oxide signaling.

Authors:  Christine Helms; Daniel B Kim-Shapiro
Journal:  Free Radic Biol Med       Date:  2013-04-26       Impact factor: 7.376

3.  Nitric oxide pathology and therapeutics in sickle cell disease.

Authors:  Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

4.  Contribution of membrane permeability and unstirred layer diffusion to nitric oxide-red blood cell interaction.

Authors:  Prabhakar Deonikar; Mahendra Kavdia
Journal:  J Theor Biol       Date:  2012-10-29       Impact factor: 2.691

5.  Spatial and temporal patterns of nitric oxide diffusion and degradation drive emergent cerebrovascular dynamics.

Authors:  William Davis Haselden; Ravi Teja Kedarasetti; Patrick J Drew
Journal:  PLoS Comput Biol       Date:  2020-07-27       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.